Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • Wednesday
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationGlobeNewsWire • Monday
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseGlobeNewsWire • 03/22/24
Matinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsGlobeNewsWire • 03/22/24
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisGlobeNewsWire • 02/20/24
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesGlobeNewsWire • 12/27/23
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAGlobeNewsWire • 12/21/23
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelGlobeNewsWire • 11/07/23
Patient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical ResolutionGlobeNewsWire • 10/11/23
Matinas BioPharma Announces Notification of NYSE American Continued Listing DeficiencyGlobeNewsWire • 09/22/23
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/06/23
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious DiseasesGlobeNewsWire • 08/22/23
Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023GlobeNewsWire • 08/02/23
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023GlobeNewsWire • 07/26/23
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023GlobeNewsWire • 05/11/23
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/10/23
Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/10/23
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023GlobeNewsWire • 05/03/23